←
Hadeesha Piyadasa98 posts
Hadeesha Piyadasa avatar

Hadeesha Piyadasa

@HadeeshaP

Asst. Prof, Biochemistry, Microbiology & Immunology @uOttawa · Scientist @CHEO Research Institute

◷ Joined March 2014▧ 36 Photos and videos
Hadeesha Piyadasa avatar
Hadeesha Piyadasa@HadeeshaP·14 Dec 2025

Thrilled to share that our paper is out in @Cancer_Cell: We apply spatial proteomics, transcriptomics, and glycomics to define tumor antigens, TME organization, and predictors of grade and survival. cell.com/cancer-cell/abstrac…

Arc Institute avatar
⟳ Hadeesha Piyadasa retweeted
Arc Institute@arcinstitute·May 26

Most spatial CRISPR screens require trade-offs in throughput or readout depth. A new preprint from @alexnevue, @Inna_Averbukh, @Davidlarastiaso & team introduces PerturbSpace: spatially resolved, multimodal, whole-transcriptome on standard single-cell workflows.

Post attachment
Hadeesha Piyadasa avatar
Hadeesha Piyadasa@HadeeshaP·14 Dec 2025

For a deeper dive into how we built this and what we found, check out the preprint post below 👇

🧵 (1/8) Today, @BenOberlton and I are excited to share the preprint of our work on: A comprehensive multi-omic study of human gliomas, spanning diagnosis, treatment, and recurrence. We address the longstanding challenge of developing effective therapies for gliomas, which have shown limited response to immunotherapy and targeted treatments compared to other malignancies. #GliomaResearch #NeuroOncology #CancerImmunotherapy biorxiv.org/content/10.1101/…

Post attachment
Noah F. Greenwald avatar
⟳ Hadeesha Piyadasa retweeted
Noah F. Greenwald@NoahGreenwald·8 Oct 2025

Thrilled to share that Nimbus, our method to robustly identify cell positivity in multiplexed imaging data, is out @naturemethods! If you've struggled with cell clustering/phenotyping in imaging data, please give it a try. nature.com/articles/s41592-0…

Hadeesha Piyadasa avatar
Hadeesha Piyadasa@HadeeshaP·17 Mar 2025

(7/8) Open source spatial multi-omics of human gliomas: We have made everything in this study freely available through the BRUCE data portal–a user-friendly web resource for quantitative analysis and visual data exploration of all extracted features and multiparameter imaging data - bruce.parkerici.org. For more details, check out the preprint - biorxiv.org/content/10.1101/…

Hadeesha Piyadasa avatar
Hadeesha Piyadasa@HadeeshaP·17 Mar 2025

(6/8) GBM survival is correlated with TME immune response: Using random forest classifiers that integrated all three modalities, we found TME glycans were the most significant spatial class for distinguishing tumor grade, while immune transcriptional pathways were the most important for predicting overall survival in patients with glioblastoma. Notably, we found almost no overlap between features predictive of grade- and outcome, highlighting distinct molecular drivers for these two clinical covariates. These findings underscore the importance of multi-omic profiling in understanding glioma progression and patient outcomes.

Post attachment
Hadeesha Piyadasa avatar
Hadeesha Piyadasa@HadeeshaP·17 Mar 2025

(5/8) TME N-glycosylation robustly encodes tumor grade: We carried out the first cohort-level spatial analysis of the tumor N-glycome to understand how this ubiquitous post-translational modification is involved in glioma pathology. We found TME glycan composition to tightly correlate with glioma grade. Grade 4 gliomas contained elevated amounts of sialylated glycans and highly branched glycans which are known to promote immune suppression and local invasion. By integrating these results with spatial proteomics and transcriptomics, we identified the cell types driving these trends and the transcriptional pathways upregulated in mediating or responding to them.

Post attachment
Hadeesha Piyadasa avatar
Hadeesha Piyadasa@HadeeshaP·17 Mar 2025

(4/8) Tumor microenvironment (TME) structure encodes recurrence and therapeutic response: In previous work, we showed that TME spatial organization predicts clinical outcomes in breast cancer. Here, we found similar TME shifts between primary and recurrent gliomas, reflecting disease progression. Notably, TME patterns in immunotherapy-treated patients were similar to those on standard care, aligning with limited differences in durable response. These spatial patterns may help track disease progression and tumor-host interactions.

Post attachment
Hadeesha Piyadasa avatar
Hadeesha Piyadasa@HadeeshaP·17 Mar 2025

(3/8) A clinical normogram for drug targetable tumor antigens: We conducted the first quantitative coexpression analysis of tumor antigens (TA) in gliomas, revealing that most tumors have <50% TA-positive cells, potentially explaining inconsistent therapy outcomes. However, combined targeting of B7H3 + EGFR could improve coverage to >90% of tumor cells in some high-grade cases, offering valuable insights for personalized treatments.

Post attachment
Hadeesha Piyadasa avatar
Hadeesha Piyadasa@HadeeshaP·17 Mar 2025

(2/8) Despite major efforts, key gaps remain in our understanding of targetable antigens, the impact of checkpoint blockade on tumor-immune dynamics, and how glycosylation shapes disease progression. In a multicenter collaboration between @Stanford, @UCLA, @UCSF, @ChildrensPhila and @cityofhope sponsored by the @parkerici, we performed a spatial multi-omic (proteome, transcriptome and N-glycome) study of clinically annotated human gliomas that included 670 samples from 310 patients. We worked closely with oncologists and pathologists to design a study that could answer outstanding questions in glioma biology that directly impact the therapy of these patients while also revealing insights into why durable remission has been elusive. Key findings listed in this thread.

Post attachment
Hadeesha Piyadasa avatar
Hadeesha Piyadasa@HadeeshaP·17 Mar 2025

🧵 (1/8) Today, @BenOberlton and I are excited to share the preprint of our work on: A comprehensive multi-omic study of human gliomas, spanning diagnosis, treatment, and recurrence. We address the longstanding challenge of developing effective therapies for gliomas, which have shown limited response to immunotherapy and targeted treatments compared to other malignancies. #GliomaResearch #NeuroOncology #CancerImmunotherapy biorxiv.org/content/10.1101/…

Post attachment
Jolene Ranek avatar
⟳ Hadeesha Piyadasa retweeted
Jolene Ranek@JoleneRanek·10 Jan 2025

Super excited to introduce QUICHE (Quantitative InterCellular Niche Enrichment) - a statistical method that can be used to discover local cellular niches differentially enriched in spatial regions, longitudinal samples, or clinical patient groups :) (1/10) biorxiv.org/content/10.1101/…

Post attachment
Noah F. Greenwald avatar
⟳ Hadeesha Piyadasa retweeted
Noah F. Greenwald@NoahGreenwald·29 Jan 2025

I’m super excited to share what I’ve been working on for the last (many) years: a spatial + genomic + transcriptomic characterization of how the breast cancer microenvironment evolves through immunotherapy! (1/x) biorxiv.org/content/10.1101/…

Patricia Favaro avatar
⟳ Hadeesha Piyadasa retweeted
Patricia Favaro@favaropb·8 Sep 2023

I am thrilled to share my preprint with @Bendall_Lab that includes a new and comprehensive phenotypic atlas of human hematopoietic progenitor cells. Check out how we reconcile the diversity of human HSPCs in the tweetorial below. biorxiv.org/content/10.1101/…

Michael Angelo avatar
⟳ Hadeesha Piyadasa retweeted
Michael Angelo@MikeAngeloLab·7 Jun 2023

Save the Date! Please join us in August for our 2nd Annual Spatial Biology Workshop! @_hubmap @ncihtan #spatialbiology @WellcomeLeap

We're excited to announce that the 2nd annual Spatial Biology Workshop will be taking place August 28th-30th at Stanford. The workshop will cover new techniques and tools for generating and analyzing spatial data, as well as new biology discovered using spatial methods.

Post attachment